Prajwal Boddu, MD
Associate Research Scientist; Heme-Onc Medicine Fellow, Medical Oncology
Research & Publications
Biography
News
Research Summary
âRNA Mediated Epigenetic Reprogramming in Clonal Myeloid Disorderâ
Dr. Manoj Pillai, Mentor
Extensive Research Description
âRNA Mediated Epigenetic Reprogramming in Clonal Myeloid Disorderâ
Dr. Manoj Pillai, Mentor
Coauthors
Selected Publications
- The FANCI/FANCD2 complex links DNA damage response to R-loop regulation through SRSF1-mediated mRNA exportOlazabal-Herrero A, He B, Kwon Y, Gupta A, Dutta A, Huang Y, Boddu P, Liang Z, Liang F, Teng Y, Lan L, Chen X, Pei H, Pillai M, Sung P, Kupfer G. The FANCI/FANCD2 complex links DNA damage response to R-loop regulation through SRSF1-mediated mRNA export. Cell Reports 2024, 43: 113610. PMID: 38165804, PMCID: PMC10865995, DOI: 10.1016/j.celrep.2023.113610.
- Impaired Early Spliceosome Complex Assembly Underlies Gene Body Elongation Transcription Defect in SF3B1K700EBoddu P, Gupta A, Roy R, De La Pena Avalos B, Herrero A, Zimmer J, Simon M, Chandhok N, King D, Neuenkirchen N, Dray E, Lin H, Kupfer G, Verma A, Neugebauer K, Pillai M. Impaired Early Spliceosome Complex Assembly Underlies Gene Body Elongation Transcription Defect in SF3B1K700E. Blood 2023, 142: 714. DOI: 10.1182/blood-2023-187303.
- Transcription Defects in SF3B1K700E Induce Targetable Alterations in the Chromatin LandscapeBoddu P, Gupta A, Roy R, Herrero A, Verma A, Neugebauer K, Pillai M. Transcription Defects in SF3B1K700E Induce Targetable Alterations in the Chromatin Landscape. Blood 2023, 142: 709. DOI: 10.1182/blood-2023-188083.
- A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignanciesBoddu P, Senapati J, RavandiâKashani F, Jabbour E, Jain N, Ayres M, Chen Y, Keating M, Kantarjian H, Gandhi V, Kadia T. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. Cancer 2022, 129: 580-589. PMID: 36448227, DOI: 10.1002/cncr.34570.
- Generation of scalable cancer models by combining AAV-intron-trap, CRISPR/Cas9, and inducible Cre-recombinaseBoddu PC, Gupta AK, Kim JS, Neugebauer KM, Waldman T, Pillai MM. Generation of scalable cancer models by combining AAV-intron-trap, CRISPR/Cas9, and inducible Cre-recombinase. Communications Biology 2021, 4: 1184. PMID: 34645977, PMCID: PMC8514589, DOI: 10.1038/s42003-021-02690-1.
- 40008 COMBINED CRISPR/CAS9 AND AAV FOR THE GENERATION OF CONDITIONAL ISOGENIC GENE KNOCK-INSBoddu P, Gupta A, Waldman T, Pillai M. 40008 COMBINED CRISPR/CAS9 AND AAV FOR THE GENERATION OF CONDITIONAL ISOGENIC GENE KNOCK-INS. Journal Of Clinical And Translational Science 2021, 5: 22-22. PMCID: PMC8827824, DOI: 10.1017/cts.2021.460.
- Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary ComplicationsKim ST, Sheshadri A, Shannon V, Kontoyiannis DP, Kantarjian H, Garcia-Manero G, Ravandi F, Im JS, Boddu P, Bashoura L, Balachandran DD, Evans SE, Faiz S, Vazquez W, Divenko M, Mathur R, Tippen SP, Gumbs C, Neelapu SS, Naing A, Wang L, Diab A, Futreal A, Nurieva R, Daver N. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. Frontiers In Immunology 2021, 11: 590494. PMID: 33552049, PMCID: PMC7859512, DOI: 10.3389/fimmu.2020.590494.
- Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML)Zeidan A, Boddu P, Wood B, Zelterman D, Little R, Ivy S, Caldwell A, Sanchez-Espiridion B, Alatrash G, Sharon E, Radich J. Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML). Blood 2020, 136: 15. DOI: 10.1182/blood-2020-139668.
- Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive ChemotherapyZeidan A, Boddu P, Wood B, Zelterman D, Little R, Ivy S, Caldwell A, Sanchez-Espiridion B, Alatrash G, Sharon E, Radich J. Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy. Blood 2020, 136: 11-12. DOI: 10.1182/blood-2020-139752.
- Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international expertsZeidan AM, Boddu PC, Patnaik MM, Bewersdorf JP, Stahl M, Rampal RK, Shallis R, Steensma DP, Savona MR, Sekeres MA, Roboz GJ, DeAngelo DJ, Schuh AC, Padron E, Zeidner JF, Walter RB, Onida F, Fathi A, DeZern A, Hobbs G, Stein EM, Vyas P, Wei AH, Bowen DT, Montesinos P, Griffiths EA, Verma AK, Keyzner A, Bar-Natan M, Navada SC, Kremyanskaya M, Goldberg AD, Al-Kali A, Heaney ML, Nazha A, Salman H, Luger S, Pratz KW, Konig H, Komrokji R, Deininger M, Cirici BX, Bhatt VR, Silverman LR, Erba HP, Fenaux P, Platzbecker U, Santini V, Wang ES, Tallman MS, Stone RM, Mascarenhas J. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. The Lancet Haematology 2020, 7: e601-e612. PMID: 32563283, PMCID: PMC7302757, DOI: 10.1016/s2352-3026(20)30205-2.
- The minimal that kills: Why defining and targeting measurable residual disease is the âSine Qua Nonâ for further progress in management of acute myeloid leukemiaBewersdorf JP, Shallis RM, Boddu PC, Wood B, Radich J, Halene S, Zeidan AM. The minimal that kills: Why defining and targeting measurable residual disease is the âSine Qua Nonâ for further progress in management of acute myeloid leukemia. Blood Reviews 2019, 43: 100650. PMID: 31883804, DOI: 10.1016/j.blre.2019.100650.
- The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemiaShallis RM, Boddu PC, Bewersdorf JP, Zeidan AM. The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia. Blood Reviews 2019, 40: 100639. PMID: 31761380, DOI: 10.1016/j.blre.2019.100639.
- Gut Microbiome Signatures Are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid LeukemiaGalloway-PeĂąa JR, Shi Y, Peterson CB, Sahasrabhojane P, Gopalakrishnan V, Brumlow CE, Daver NG, Alfayez M, Boddu PC, Khan A, Wargo JA, Do KA, Jenq RR, Kontoyiannis DP, Shelburne SA. Gut Microbiome Signatures Are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia. Clinical Infectious Diseases 2019, 71: 63-71. PMID: 31436833, PMCID: PMC7312220, DOI: 10.1093/cid/ciz777.
- Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemiaShallis RM, Bewersdorf JP, Boddu PC, Zeidan AM. Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia. Expert Review Of Anticancer Therapy 2019, 19: 717-729. PMID: 31422721, DOI: 10.1080/14737140.2019.1652095.
- SMAC mimetics as potential cancer therapeutics in myeloid malignanciesBoddu P, Carter BZ, Verstovsek S, Pemmaraju N. SMAC mimetics as potential cancer therapeutics in myeloid malignancies. British Journal Of Haematology 2019, 185: 219-231. PMID: 30836448, DOI: 10.1111/bjh.15829.
- What are the most promising new agents in myelodysplastic syndromes?Chandhok NS, Boddu PC, Gore SD, Prebet T. What are the most promising new agents in myelodysplastic syndromes? Current Opinion In Hematology 2019, 26: 77-87. PMID: 30632987, DOI: 10.1097/moh.0000000000000483.
- Idiopathic granulomatous mastitis mimicking inflammatory breast carcinoma: What are the odds?Zulfiqar B, Appalaneni U, Ahmed B, Hassan A, Boddu P, Carey A. Idiopathic granulomatous mastitis mimicking inflammatory breast carcinoma: What are the odds? IDCases 2016, 6: 83-84. PMID: 27790396, PMCID: PMC5081417, DOI: 10.1016/j.idcr.2016.10.006.
- The impact of diagnostic discrepancies in aortic dissection managementHassan A, Zabad A, Candrasekaran M, Mohammed A, Mahmoud S, Boddu P. The impact of diagnostic discrepancies in aortic dissection management. International Journal Of Medical Research & Health Sciences 2016, 5: 107. DOI: 10.5958/2319-5886.2016.00023.0.
- Baclofen-induced toxic encephalopathy in end-stage renal disease: should we be more careful?Mohammed A, Hassan A, Boddu P. Baclofen-induced toxic encephalopathy in end-stage renal disease: should we be more careful? Asian Pacific Journal Of Health Sciences 2016, 3: 53-55. DOI: 10.21276/apjhs.2016.3.1.9.
- Uncommon Cause of Odynophagia: Case Report of Esophageal Pemphigus VulgarisPoowanawittayakom N, Boddu P, Flicker M. Uncommon Cause of Odynophagia: Case Report of Esophageal Pemphigus Vulgaris. The American Journal Of Gastroenterology 2014, 109: s1-s2. DOI: 10.14309/00000434-201410002-00004.
- Uncommon Cause of Right Upper Quadrant Pain: A Case Report of Omental InfarctionBoddu P, Poowanawittayakom N, Shah R, Flicker M. Uncommon Cause of Right Upper Quadrant Pain: A Case Report of Omental Infarction. The American Journal Of Gastroenterology 2014, 109: s103-s104. DOI: 10.14309/00000434-201410002-00345.